Global Blood Glucose Monitoring System Market Size Likely to Grow at a CAGR of 8.9% By 2035

Market Size and Growth

The market size of global blood glucose monitoring systems will be estimated at USD 16.8 billion in 2025 and is expected to grow to between USD 18.3 billion in 2026 and about USD 39.4 billion by 2035, with a current CAGR (compound annual growth rate) of 8.9% during the period of 2026 to 2035.

Blood Glucose Monitoring System Market Revenue and Trends

Blood glucose monitoring system (BGMS) is a test and management tool for diagnosing and managing glucose levels in the blood to aid the management of diabetes. The BGMS is either a portable Glucometer device to give periodic readings by testing samples of blood or a more advanced sensor-based device that can monitor changes in glucose levels over time. Blood glucose monitoring systems can provide information both graphically and as data on changes in blood sugars over time in order for patients to understand how their eating, exercise, medication, and stress levels influence their blood sugars. Blood glucose monitoring systems are therefore able to inform treatment and lifestyle changes over the short and long term in order to prevent acute hypoglycemic events as well as achieve metabolic control in the long term.

What are the Factors That Have a Significant Contribution to the Growth of the Blood Glucose Monitoring System Market?

The growing introduction of AI-enabled blood glucose monitoring systems is expected to offer a potential opportunity for market growth. For instance, in November 2025, Roche has announced the availability of its Accu-Chek® SmartGuide continuous glucose monitoring (CGM) solution in the Middle East. The rollout will be from Kuwait, Qatar, KSA and other markets, starting with the UAE in the very near future. This is a major milestone and means people living with diabetes aged 18+ can now access the benefits of the solution ‘s advanced glucose monitoring and Artificial Intelligence (AI)-enabled predictions within the healthcare community. Diabetes is one of the most serious healthcare challenges of today. Over 85 million people are living with the condition across the Middle East and North Africa (MENA) region. When unmanaged, diabetes can cause secondary complications such as cardiovascular disease, kidney disease, nerve damage, blindness, lower limb amputation, and mental health problems.

Also, the growing prevalence of home healthcare is also propelling the growth of the blood glucose monitoring system market as patients seek a more comfortable, cost-efficient disease management strategy outside clinics. With the increasing number of people suffering from chronic diseases such as diabetes, there is a need for continuous monitoring of glucose levels without multiple trips to the hospital. Blood glucose monitoring systems provide portable and easy-to-use devices for patients to avail themselves of a rapid and cost-efficient way of determining glucose levels at home, which in turn enhances patient compliance and early diagnosis. This trend is further facilitated by the opening up of low-cost connected devices, remote monitoring, and telehealth services that allow a doctor to track a patient’s data in real time.

Regional Insights

North America held the highest market share in 2025. The continued revenue growth of the market for blood glucose monitors in the region is greatly influenced by the existence of dominant industry stakeholders, ongoing product innovations, and government subsidies.

Besides, the Asia Pacific market is expected to capture a significant revenue share in 2025. The increasing number of the geriatric population and growing product launches drive the market growth.

Report Scope

Recent Developments

• In August 2024, Abbott announced a unique global partnership with Medtronic to develop an integrated continuous glucose monitoring (CGM) system based on Abbott’s most advanced, world-leading FreeStyle Libre technology, which will connect with Medtronic’s automated insulin delivery (AID) and smart insulin pen systems. The integration of Abbott’s CGM sensor with Medtronic’s AID algorithms will enable automatic insulin adjustments to keep glucose within range. The CGM sensor, designed to work exclusively with Medtronic devices, will be developed by Abbott and sold by Medtronic. (https://en.caclp.com/industry-news/2943.html)

List of the prominent players in the Blood Glucose Monitoring System Market:

• Insulet Corporation
• Medtronic plc
• GlucoRx Limited
• Zhejiang POCTech Co. Ltd
• i-SENS Inc.
• Nemaura Medical Inc.
• Sinocare Inc.
• Bionime
• AgaMatrix
• Senseonics Holdings Inc.
• Hoffmann-La Roche Ltd
• Dexcom Inc.
• Sanofi
• Novo Nordisk
• Abbott Laboratories
• Ypsomed Holdings
• Glysens Incorporated
• Others